2023-505322-34-00暂停1 期
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors
Beigene Ltd.3 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2023年12月4日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 暂停
- 发起方
- 入组人数
- 45
- 试验地点
- 3
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
BeiGene Clinical Support
Scientific
Beigene Ltd.
研究点 (3)
Loading locations...
相似试验
暂停
1 期
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab, in Patients With Advanced or Metastatic Solid Tumors2023-503996-38-00Beigene Ltd.60
招募中
1 期
A Phase 1 Study to Investigate the Safety and Tolerability of the Study Drug GB-0895 in Mild to Moderate Asthma Patients or Single Dose in Chronic Obstructive Pulmonary Disease (COPD)2023-507611-35-00Generate Biomedicines Inc.70
撤回
1 期
A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of a pDNA Vaccine Candidate Against COVID-19 in Healthy Adults2023-505135-12-00Imam Abdulrahman Bin Faisal University60
已完成
1 期
A Study to Evaluate the Safety and Tolerability of JNJ-77730614 When Given as Single and Multiple Doses to Healthy Participants to Assess How Long JNJ 77730614 Stays in the Body (Pharmacokinetics) and How the Body Responds to it (Pharmacodynamics)2023-505684-36-00Janssen - Cilag International92
招募中
1 期
An early Phase 1b Study to assess how safe and effective is the treatment with drugs, called Mosunetuzumab or Glofitamab in Combination with drugs called, CC-220 and CC-99282 in Patients with B-Cell Non-Hodgkin Lymphoma.2023-505185-28-00F. Hoffmann-La Roche AG52